Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01170286 · ClinicalTrials.gov registry record · Phase 1
Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy
A Phase 1 study, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT01170286 is a Phase 1 study that has completed, run by DBV Technologies. The registered enrollment target is 100 participants.
The verdict
NCT01170286, a Phase 1 study, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this phase 1b study is to evaluate the safety and tolerability of repeated epicutaneous applications of peanut proteins using a patch delivery system (Viaskin device) in peanut allergic subjects.
Interventions
- BIOLOGICAL Whole peanut extract
- BIOLOGICAL Placebo formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01170286
The ClinicalTrials.gov registry entry for NCT01170286 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DBV Technologies, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Whole peanut extract is the first listed.
NCT01170286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01170286 about?
NCT01170286 is a clinical study titled "Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy". The purpose of this phase 1b study is to evaluate the safety and tolerability of repeated epicutaneous applications of peanut proteins using a patch delivery system (Viaskin device) in peanut allergic subjects.
What is the current status of trial NCT01170286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2010-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01170286?
The interventions under investigation include: Whole peanut extract (BIOLOGICAL), Placebo formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT01170286?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.